arrow
M

Michael Levy

Mass General Brigham
H指数:64
被引数:2.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Mapping myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) and neuromyelitis optica spectrum disorders (NMOSD): A global review of publicly listed patient disease registries and databases

髓鞘少突胶质细胞糖蛋白抗体相关疾病(MOGAD)和视神经脊髓炎谱系障碍(NMOSD)的全球映射:对公开列出的患者疾病登记册和数据库的综述

2026-11-110
PRE
CD4+ T cells reactive to Epstein-Barr virus late lytic antigens are enriched in individuals with multiple sclerosis

CD4<sup>+</sup>T细胞在多发性硬化症患者中富集,并对EB病毒晚期溶细胞性抗原具有反应性

2026-07-150
PRE
Comparative Effectiveness of Disease-Modifying Treatments in Double Seronegative Neuromyelitis Optica Spectrum Disorder (vol. 13, e200514, 2026)

双血清阴性视神经脊髓炎谱系障碍中疾病修正治疗的有效性比较(卷13,e200514,2026)

2026-05-010
PRE
Satralizumab treatment in adults with aquaporin-4 immunoglobulin G-seropositive neuromyelitis optica spectrum disorder in clinical practice

成年水通道蛋白-4免疫球蛋白G血清阳性视神经脊髓炎谱系障碍患者中的萨特拉利珠单抗治疗在临床实践中的应用

2025-12-090
OA
A Multi-Center Retrospective Cohort Study of Neurosarcoidosis Myelitis: Current Observations and Future Directions

多中心回顾性队列研究:神经肉芽肿性脊髓炎:当前观察与未来方向

2025-09-170
OAAI
ACT with NMOSD: A targeted, telehealth-delivered mental health intervention for patients & caregivers

ACT with NMOSD:一种针对患者及照护者的、通过远程医疗提供的心理健康干预措施

2025-07-220
PRE
Satralizumab treatment in patients with AQP4-IgG-seropositive neuromyelitis optica spectrum disorder after rituximab treatment: A case series

Satralizumab治疗在AQP4-IgG血清阳性的视神经脊髓炎谱系障碍患者中的应用:一项病例系列研究

2025-06-010
PRE